More CAR-T: Looking Back to Go Forward in CAR-T Cell Therapy in R/R CLL

[Jm954]

Long-term data from a phase 1 study investigating anti-CD19 chimeric antigen receptor (CAR) T-cell (CAR-T) therapy in patients with R/R CLL showed that the product appeared to be safe, and that prior lymphodepleting chemotherapy is necessary.

The data, published in JCI Insight, also brought to the forefront ibrutinib as a possible means of enhancing CAR-T’s efficacy in CLL.

Approximately a quarter of patients with relapsed or refractory CLL achieve durable responses to anti-CD19 CAR-T.

Overall, 6 of the 16 CLL patients (38%) achieved an objective response, but among patients who received lymphodepleting chemotherapy, the response rate was 50% (6 of 12 patients). The response rate increased to 80% (4 of 5 patients) when only patients who received concurrent ibrutinib in addition to lymphodepleting chemotherapy were considered.

More here: cancertherapyadvisor.com/ho...

Jackie

[DriedSeaweed]

Does Car-T cause neutropenia like most other treatments?

[Jm954 Administrator in reply to DriedSeaweed]

Yes

my.clevelandclinic.org/heal...

[DriedSeaweed in reply to Jm954]

I wonder if it is because they pretreat with other drugs before the car-t process.

[Jm954 Administrator in reply to DriedSeaweed]

That could definitely be a contributing factor.

Jackie

[Bell53]

I am assuming the population pre-treated with ibrutinib were continuing to have effective disease control with ibrutinib before starting Car- t

[Jm954 Administrator in reply to Bell53]

Yes and they were having concurrent Ibrutinib.

[Smakwater]

Good read Jackie,

My take away,

1). “It’s very small numbers of patients, and we would not want to attempt to draw definitive conclusions, but it’s consistent with other lines of evidence to suggest that ibrutinib may modulate T-cell phenotypes and function,”

2). “It certainly makes sense to test [adding ibrutinib] because if you can make the responses better, that certainly should be a goal, because toxicities are seemingly not so severe,”

Reasonably Anxious to see the CAR T end point. Appears to have great potential.

JM